Details of the SBP | SYNBIP

General Information of Synthetic Binding Protein (SBP) (ID: SBP002009)
SBP Name	Anticalin Cinrebafusp alfa
Synonyms	PRS-343
Design Method	Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status	Phase I

Protein Scaffold Information of This SBP
Scaffold ID	PS011 Scaffold Info					[1] , []
Scaffold Name	Anticalin
Scaffold Class	Non-Antibody
Fold Type	One Alpha-Helix + Beta-Sheets + Loops

Binding Target(s) of This SBP (BTS)

BTS Name	Details	Mechanism	Application	Affinity	Research Organization	Ref
Tumor necrosis factor receptor superfamily member 9	BTS Info	Agonist	Solid tumour/cancer [ICD-11: 2A00-2F9Z]	N.A.	Pieris AG	[1] , []
Receptor tyrosine-protein kinase erbB-2	BTS Info	Binder	Solid tumour/cancer [ICD-11: 2A00-2F9Z]	N.A.	Pieris AG	[1] , []

Clinical Trial Information of This SBP
NCT03330561	Click to show the Detail
Indication	HER2-Positive Advanced or Metastatic Solid Tumor
Phase	Phase I
Title	A?Phase I, Open-Label, Dose Escalation Study of?PRS-343?in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Status	Suspended?(Partial Clinical Hold)
Sponsor	Pieris Pharmaceuticals
NCT03650348	Click to show the Detail
Indication	HER2-Positive Advanced or Metastatic Solid Tumor
Phase	Phase I
Title	A Phase Ib, Open-Label, Dose Escalation Study of?PRS-343?in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Status	Suspended?(Partial Clinical Hold)
Sponsor	Pieris Pharmaceuticals
NCT05190445	Click to show the Detail
Indication	HER2-positive Gastric Cancer
Phase	Phase II
Title	Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Status	Active, not recruiting
Sponsor	Pieris Pharmaceuticals, Inc.

References

1

Recent advances in the development of novel protein scaffolds based therapeutics. Int J Biol Macromol. 2017 Sep;102:630-641.